By Ludwig Burger and Riham Alkousaa (Reuters) – German healthcare group Fresenius has cut its 2022 guidance for the second time on persistent cost inflation and staff shortages with its new CEO pledging a review of all its diversified businesses. The company’s shares gained 4% on Monday after months of losses on hopes that a new leadership team will right the ship. In a statement on Sunday, the drugmaker and healthcare services company said its adjusted net income would likely fall 10% this year, excluding foreign exchange effects, having previously indicated a decline in a “single-digit perce…